Registr Tulung: Analýza dat pacientů s neskvamózní formou (adenokarcinom, velkobuněčný karcinom) nsclc a ps 0-1 léčených erlotinibem ve 2. linii léčby

• Title in English: The TULUNG Register. An analysis of data of non-squamous (adenocarcinoma, large cell carcinoma) of NSCLS patients, performance status 0-1, treated with erlotinib as second-line therapy
• Authors: ROUBEC Jaromír; HEJDUK Karel; BORTLÍČEK Zbyněk; SKŘIČKOVÁ Jana; PEŠEK Miloš; ZATLOUKAL P.; KOLEK V.; SALAJKA F.; KOUBKOVÁ L.; TOMÍŠKOVÁ Marcela; GRYGÁRKOVÁ Y.; HAVEL L.; HRNČIARIK M.; ZEMANOVÁ M.; SIXTOVÁ D.; ČOUPKOVÁ H.; KOŠATOVÁ K.
• Year of publication: 2013
• Type: Conference abstract
• MU Faculty or unit: Faculty of Medicine
• Description: In total, 521 patients (of whom 51.2% were women) received erlotinib. Most of them (86.1%) ha metastatic disease at the start of second-line treatment. In 410 patients, the tratment was terminated either for progression of the disease (74.6%) or death (11.5%).